Oxford/AstraZeneca study supports UK decision to delay second ...


Oxford/AstraZeneca study supports UK decision to delay second doses

New Oxford analysis, not yet peer-reviewed, shows single jab to be 76% effective for up to 12 weeks

Donato Paolo Mancini and Sarah Neville

A single dose of the Oxford/AstraZeneca coronavirus vaccine is 76% effective from three to 12 weeks after the injection, according to an analysis of trial data that could boost confidence in the UK’s decision to delay second doses and vaccinate more people more quickly.

In a paper published on Tuesday but not yet peer-reviewed, researchers at Oxford University said the single dose had shown efficacy of 76% from 22 up to 90 days post-vaccination, “with the protection showing little evidence of waning in this period”.

The researchers also found that spacing the first and second doses over a longer period yielded better long-term efficacy — a fact previously defended theoretically, but not shown empirically with large-scale evidence for coronavirus vaccines. Vaccine efficacy rose to 82.4% following a second doses after 12 weeks, Oxford said...

This article is reserved for Sunday Times Daily subscribers.
A subscription gives you full digital access to all Sunday Times Daily content.

Sunday Times Daily

Already subscribed? Simply sign in below.

Questions or problems?
Email helpdesk@timeslive.co.za or call 0860 52 52 00.

Previous Article